Oncologic safety and reproductive outcomes of conservative therapy for early-stage endometrial disease

Read full text Summarise with VIRAT
Authors: Aisha Jamil, Ghulam Sughra, Ghazala Dawood Abbasi, Soukaina Adane, Monica Punshi, Mobashara Ghulam Muhammad, Marium Nausherwan, Yamina Ishtiaq, Muhammad Dawood Hazoor
Cited by: 0
References: 27

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND Endometrial cancer (EC) is the most common gynecologic malignancy, with rising incidence in young women desiring fertility preservation. Traditional hysterectomy precludes childbearing, prompting fertility-sparing management (FSM) with progestins for atypical hyperplasia (AH) and early-stage, low-grade EC. However, concerns persist regarding oncologic safety, recurrence, and reproductive success. Biomarkers like Ki-67, human epididymis protein 4, and molecular classifications may enhance prognostic stratification. This study hypothesizes that FSM yields favorable outcomes, with biomarkers independently predicting recurrence risk. AIM To assess oncologic and reproductive outcomes of FSM in AH and early-stage EC, evaluating biomarker predictive value. METHODS Multicenter retrospective cohort study at tertiary hospitals, including 234 women aged 18-45 years with AH or FIGO stage IA grade 1 endometrioid EC (2015-2023). Participants were selected via medical records review with records with estrogen/progesterone positivity and no invasion on imaging. Interventions included levonorgestrel-intrauterine device, megestrol acetate, or combinations, with 3-6 monthly biopsies. Key analyses: Kaplan-Meier for survival, multivariable Cox models for recurrence predictor. RESULTS Among 234 patients [126 AH, 108 grade 1 endometrioid adenocarcinoma (G1 EA)], complete response (CR) was 79.9% (187; AH 84.9% vs G1 EA 74.1%, P = 0.249), with mean time to CR 4.0 ± 1.5 months. Recurrence occurred in 25.1% (47/187; mean time 11.4 ± 4.6 months), higher in G1 EA [35.0% vs AH 17.8%, odds ratio = 2.51, 95% confidence interval (CI): 1.25-5.04]. Multivariable analysis showed body mass index > 30 kg/m2 [hazard ratio (HR) = 2.95, 95%CI: 1.12-7.76, P = 0.029], Ki-67 > 20% (HR = 3.12, 95%CI: 1.25-7.81, P = 0.015), and human epididymis protein 4 > 50 pmol/L (HR = 2.78, 95%CI: 1.10-7.02, P = 0.031) predicted recurrence. Molecular subtypes influenced CR: No specific molecular profile 78.4% vs mismatch repair deficient 48.6%. Among 117 attempting pregnancy, live birth rate was 50.4% (59). Disease-specific survival was 99.1%. CONCLUSION FSM achieves high response rates and reproductive success with excellent survival; biomarkers independently predict recurrence, enabling personalized risk stratification.

Fields of Study & Subjects

Endometrial and Cervical Cancer Treatments Ovarian cancer diagnosis and treatment Breast Cancer Treatment Studies

Publication details

Journal / source
World Journal of Clinical Oncology
Volume
17
Issue
3
Publication date
23 March 2026
Language
EN